Ticker

Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) grew first-half revenue to US$1.6 million and trimmed its underlying EBITDA loss, but said full-year sales are now expected to come in at around US$4 million as healthcare-system integrations take longer to convert into revenue. The kidney disease diagnostics group said revenue for the six months to 31 December 2025 rose from US$1.3 million a year earlier, while…

Renalytix PLC (AIM:RENX, OTC:RNLXY, FRA:2O9) shares dropped 25% to 4.25p after the company posted first-half revenues of $1.6 million and flagged slower-than-expected progress in rolling out its kidney disease diagnostic test. The company, which develops the FDA-approved and Medicare-reimbursed kidneyintelX.dkd test for early-stage diabetic kidney disease, said full-year revenue is now expected to reach $4 million,…